ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
조현병 치료제 시장 규모는 향후 수년간 강력한 성장세를 보일 것으로 예상되며, 2029년까지 연평균 6.3%의 성장률(CAGR)을 기록하며 108억 5,000만 달러에 달할 것으로 예측됩니다. 예측 기간 중 예상되는 성장은 보다 효과적인 치료 결과에 대한 수요 증가, 항정신병 약물의 발전에 초점을 맞춘 연구개발 활동 증가, 제품 출시, 규제 당국의 승인, 정신 질환에 대한 신약 개발에 대한 투자 증가 등의 요인에 기인합니다. 기타 기여 요인으로는 정신건강 치료에 대한 보험 적용 범위 확대, 정부의 구상과 지원 등이 있습니다. 이 기간 중 예상되는 주요 동향으로는 지속형 주사제 개발, 모바일 앱 및 웨어러블과 같은 디지털 툴의 도입, 글루타메이트 작용성 경로를 표적으로 하는 약물의 출현, 유전자 연구 및 바이오마커 연구의 활용, 보조요법에 대한 관심 증가 등을 들 수 있습니다.
조현병 환자 수 증가는 조현병 치료제 시장의 성장을 촉진할 것으로 예측됩니다. 조현병은 왜곡된 사고, 지각, 감정, 행동을 특징으로 하는 만성 정신질환으로 환각과 망상을 유발하는 경우가 많습니다. 유전적 소인, 환경적 스트레스 요인, 약물 남용, 뇌내 화학물질의 불균형 등이 조현병 환자 증가에 기여하고 있습니다. 조현병 치료제는 증상 관리에 도움이 되고 환자의 일상 생활에 미치는 영향을 줄이고 전반적인 치료 결과를 개선합니다. 예를 들어 2024년 2월 미국 생물 의학 도서관인 국립 의학 도서관은 미국 인구의 정신 분열증 및 관련 정신병 장애의 유병률이 0.25%에서 0.64%로 보고했습니다. 또한 2024년 1월 캐나다에 본부를 둔 비영리 단체인 브리티시컬럼비아 정신분열병 협회는 정신분열병이 정신질환으로 인한 입원의 주요 원인으로 일반 병원 입원의 19.9%, 정신병원 입원의 30.9%를 차지한다고 발표했습니다. 결과적으로 조현병 환자 수 증가가 조현병 치료제 시장의 성장을 가속할 것으로 보입니다.
조현병 치료제 시장의 주요 기업은 환자 치료와 치료 결과를 개선하기 위해 조현병 경구용 약물과 같은 첨단 치료법 개발에 주력하고 있습니다. 조현병 경구용 약물은 조현병의 증상을 관리하기 위해 입으로 복용하는 약물로, 일반적으로 기분과 사고, 지각을 안정시키는 항정신병 약물이 사용됩니다. 예를 들어 2024년 9월 미국 바이오 제약회사 브리스톨 마이어스 스퀴브(Bristol-Myers Squibb)는 성인 조현병 치료를 위한 혁신적인 경구용 약물인 코벤파이(Corvenfi)가 미국 식품의약국(FDA)의 승인을 받았다고 발표했습니다. 이 획기적인 약물은 도파민 수용체가 아닌 콜린성 수용체를 표적으로 삼아 기존 항정신병약물과는 다른 새로운 접근법을 제공하는 크산멜린과 염화트로스피움의 조합입니다. 이러한 독특한 기전을 통해 기존 항정신병약물의 일반적인 부작용을 최소화하면서 망상, 사고의 혼란과 같은 증상을 완화할 수 있으며, 코벤피는 조현병 치료의 유망한 대안이 될 수 있습니다.
목차
제1장 개요
제2장 시장의 특징
제3장 시장 동향과 전략
제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나바이러스의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 조현병 치료제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 용도 산업의 분석
세계의 조현병 치료제 시장 : 성장률 분석
세계의 조현병 치료제 시장 실적 : 규모와 성장, 2019-2024
세계의 조현병 치료제 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계 조현병 치료제 TAM(Total Addressable Market)
제6장 시장 세분화
세계의 조현병 치료제 시장 : 치료 클래스별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제2세대
제3세대
기타 치료 클래스
세계의 조현병 치료제 시장 : 치료별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
경구
주사제
세계의 조현병 치료제 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원 약국
소매 약국
온라인 약국
기타 유통 채널
세계의 조현병 치료제 시장, 제2세대의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
Risperidone
Olanzapine
Quetiapine
Aripiprazole
Paliperidone
Ziprasidone
기타
세계의 조현병 치료제 시장, 제3세대의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
Brexpiprazole
Cariprazine
기타
세계의 조현병 치료제 시장, 기타 치료 클래스의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제1세대 항정신병약
병용요법
기타
제7장 지역별·국가별 분석
세계의 조현병 치료제 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 조현병 치료제 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
조현병 치료제 시장 : 경쟁 구도
조현병 치료제 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
Merck & Co. Overview, Products and Services, Strategy and Financial Analysis
Novartis AG Overview, Products and Services, Strategy and Financial Analysis
Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 대기업과 혁신적 기업
Bristol Myers Squibb
AstraZeneca PLC
Eli Lilly and Company
Amgen Inc.
F. Hoffmann-La Roche Ltd.
Teva Pharmaceutical Industries Ltd.
UCB S.A.
Sun Pharmaceutical Industries Ltd.
AbbVie Inc.
H. Lundbeck A/S
Cipla Ltd.
Lupin Limited
Alkermes plc
Vanda Pharmaceuticals Inc.
Sumitomo Pharma Co. Ltd.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 합병과 인수
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
조현병 치료제 시장 2029 : 새로운 기회를 제공하는 국가
조현병 치료제 시장 2029 : 새로운 기회를 제공하는 부문
조현병 치료제 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁의 전략
제36장 부록
KSA
영문 목차
영문목차
Schizophrenia medications are designed to alleviate the symptoms of schizophrenia, a chronic mental disorder that impacts thoughts, perceptions, emotions, and social interactions. These drugs work by addressing chemical imbalances in the brain, particularly those involving dopamine and serotonin, which helps reduce psychotic symptoms, stabilize mood, and improve cognitive abilities, leading to better daily functioning and increased independence.
The primary therapeutic categories of schizophrenia drugs include second-generation, third-generation, and other types. Second-generation antipsychotics, also known as "atypical" antipsychotics, treat schizophrenia by targeting dopamine and serotonin receptors. These drugs provide symptom relief with a reduced risk of movement disorders compared to first-generation antipsychotics. They are available in various forms, such as oral and injectable, and are distributed through multiple channels, including hospital pharmacies, retail pharmacies, online pharmacies, and other outlets.
The schizophrenia drugs market research report is one of a series of new reports from The Business Research Company that provides schizophrenia drugs market statistics, including the schizophrenia drugs industry global market size, regional shares, competitors with the schizophrenia drugs market share, detailed schizophrenia drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the schizophrenia drugs industry. These schizophrenia drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The schizophrenia drugs market size has grown strongly in recent years. It will grow from $7.96 billion in 2024 to $8.49 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth during the historic period can be attributed to several factors, including the introduction of newer drugs such as second- and third-generation antipsychotics, an increase in the prevalence of mental health disorders and schizophrenia, heightened awareness about mental health, a rise in mental health awareness programs by both government and non-government organizations, and a growing geriatric population.
The schizophrenia drugs market size is expected to see strong growth in the next few years. It will grow to $10.85 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth anticipated during the forecast period can be attributed to factors such as the increasing demand for more effective treatment outcomes, a rise in research and development activities focused on advancements in antipsychotic drugs, product launches, and regulatory approvals, as well as growing investments in the development of new pharmaceuticals for mental health conditions. Other contributing factors include better insurance coverage for mental health treatments, government initiatives, and support. Key trends expected during this period include the development of long-acting injectable formulations, the introduction of digital tools such as mobile apps and wearables, the emergence of drugs targeting glutamatergic pathways, the use of genetic and biomarker research, and an increasing focus on adjunct therapies.
The increasing number of schizophrenia cases is expected to drive the growth of the schizophrenia drugs market. Schizophrenia is a chronic mental disorder characterized by distorted thoughts, perceptions, emotions, and behaviors, often leading to hallucinations and delusions. Factors such as genetic predisposition, environmental stressors, substance abuse, and imbalances in brain chemistry are contributing to the rise in schizophrenia cases. Schizophrenia medications help manage symptoms, reducing the disorder's impact on patients' daily lives and improving overall treatment outcomes. For example, in February 2024, the National Library of Medicine, a US-based biomedical library, reported that the prevalence of schizophrenia and related psychotic disorders in the US population ranged from 0.25% to 0.64%. Additionally, in January 2024, the British Columbia Schizophrenia Society, a nonprofit organization based in Canada, stated that schizophrenia is a leading cause of hospitalization for mental illnesses, accounting for 19.9% of general hospital admissions and 30.9% of psychiatric hospital stays. As a result, the increasing number of schizophrenia cases will fuel the growth of the schizophrenia drugs market.
Leading companies in the schizophrenia drugs market are focused on developing advanced treatments, such as oral medications for schizophrenia, to improve patient care and treatment outcomes. Oral medications for schizophrenia are taken by mouth to manage the symptoms of the disorder, typically involving antipsychotics that help stabilize mood, thoughts, and perceptions. For example, in September 2024, Bristol Myers Squibb, a US-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved Cobenfy, an innovative oral medication for treating schizophrenia in adults. This groundbreaking drug combines xanomeline and trospium chloride, offering a new approach compared to traditional antipsychotics by targeting cholinergic receptors rather than dopamine receptors. This unique mechanism has the potential to alleviate symptoms such as delusions and disorganized thinking while minimizing the common side effects associated with older antipsychotic medications, making Cobenfy a promising alternative in schizophrenia treatment.
In March 2024, Bristol Myers Squibb, a US-based pharmaceutical company, acquired Karuna Therapeutics for $14 billion. This acquisition is expected to enhance Bristol Myers Squibb's neuroscience portfolio by adding KarXT, a new antipsychotic, and expanding its pipeline with potential treatments for schizophrenia, Alzheimer's disease, and other mental health disorders. Karuna Therapeutics, a US-based biopharmaceutical company, specializes in producing drugs for schizophrenia.
Major players in the schizophrenia drugs market are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co., Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca PLC, Eli Lilly and Company, Amgen Inc., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., UCB S.A., Sun Pharmaceutical Industries Ltd., AbbVie Inc., H. Lundbeck A/S, Cipla Ltd., Lupin Limited, Alkermes plc, Vanda Pharmaceuticals Inc., Sumitomo Pharma Co. Ltd., Mylan NV, Otsuka Pharmaceutical Co. Ltd., Reviva Pharmaceuticals Holdings Inc., Lifegenix, and Flagship Biotech International Pvt. Ltd.
North America was the largest region in the schizophrenia drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in schizophrenia drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the schizophrenia drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The schizophrenia drugs market consists of sales of transdermal patches, liquid formulations, and adjunctive therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Schizophrenia Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on schizophrenia drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for schizophrenia drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The schizophrenia drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Therapeutic Class: Second Generation; Third Generation; Other Therapeutic Classes
2) By Treatment: Oral; Injectable
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
Subsegments:
1) By Second Generation: Risperidone; Olanzapine; Quetiapine; Aripiprazole; Paliperidone; Ziprasidone; Others
2) By Third Generation: Brexpiprazole; Cariprazine; Others
3) By Other Therapeutic Classes: First-Generation Antipsychotics; Combination Therapies; Others
Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; Merck & Co.; Novartis AG; Sanofi S.A.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Schizophrenia Drugs Market Characteristics
3. Schizophrenia Drugs Market Trends And Strategies
4. Schizophrenia Drugs Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Schizophrenia Drugs Growth Analysis And Strategic Analysis Framework
5.1. Global Schizophrenia Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Schizophrenia Drugs Market Growth Rate Analysis
5.4. Global Schizophrenia Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Schizophrenia Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Schizophrenia Drugs Total Addressable Market (TAM)
6. Schizophrenia Drugs Market Segmentation
6.1. Global Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Second Generation
Third Generation
Other Therapeutic Classes
6.2. Global Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Injectable
6.3. Global Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Other Distribution Channels
6.4. Global Schizophrenia Drugs Market, Sub-Segmentation Of Second Generation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Risperidone
Olanzapine
Quetiapine
Aripiprazole
Paliperidone
Ziprasidone
Others
6.5. Global Schizophrenia Drugs Market, Sub-Segmentation Of Third Generation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Brexpiprazole
Cariprazine
Others
6.6. Global Schizophrenia Drugs Market, Sub-Segmentation Of Other Therapeutic Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
First-Generation Antipsychotics
Combination Therapies
Others
7. Schizophrenia Drugs Market Regional And Country Analysis
7.1. Global Schizophrenia Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Schizophrenia Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
